论文部分内容阅读
目的:评价基因重组人生长激素(rhGH)治疗青春期前特发性生长激素缺乏症(IGHD)患儿6个月的疗效和安全性。方法:对49例IGHD患儿进行rhGH治疗,每晚睡前皮下注射0．5IU·kg~(-1),每周分5次注射,共26周。评价治疗前后身高、生长速度、身高标准差计数(SDS)等指标。结果:在rhGH治疗期间,46例患儿生长速度由每年(2．5±1．0)cm提高到(11．5±2．5)cm(P＜0．005)。身高SDS由治疗前(-4．2±1．8)增为(-3．7±1．8)。同时患儿13和26周血清胰岛素样生长因子(IGF-1)和IGF结合蛋白(IGFBP,)水平均较治疗前明显升高(P＜0．05)。其体重与骨龄无明显变化。治疗后共有15．7%患儿出现甲状腺功能降低,抗hGH抗体阳性率为21．7%,但所有这些现象均未影响患者体格的线性增长。在治疗期间所有患者肝肾功能、血尿常规和代谢性指标(如血糖和血脂水平)等均保持在正常范围。结论:rhGH是治疗IGHD安全有效的药物。
AIM: To evaluate the efficacy and safety of recombinant human growth hormone (rhGH) for 6 months in children with idiopathic growth hormone deficiency (IGHD) before puberty. Methods: 49 cases of children with IGHD were treated with rhGH. The rats were subcutaneously injected with 0.5IU · kg ~ (-1) every night before going to bed, 5 times a week for 26 weeks. Before and after treatment to assess the height, growth rate, height and standard deviation count (SDS) and other indicators. Results: During the rhGH treatment, the growth rate of 46 children increased from (2.5 ± 1.0) cm to (11.5 ± 2.5) cm (P <0.005) per year. Height SDS increased from (-4.2 ± 1.8) to (-3.7 ± 1.8) before treatment. At the same time, the levels of serum insulin-like growth factor (IGF-1) and IGF-binding protein (IGFBP) in children at 13 and 26 weeks were significantly higher than those before treatment (P <0.05). No significant change in body weight and bone age. After treatment, 15.7% of the patients had hypothyroidism, and the positive rate of anti-hGH antibody was 21.7%. All of these phenomena did not affect the linear growth of the patient’s body. During the treatment of all patients liver and kidney function, blood and urine routine and metabolic indicators (such as blood glucose and blood lipid levels) were maintained within the normal range. Conclusion: rhGH is a safe and effective drug for the treatment of IGHD.